CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

Wall Street Analyst Weigh In CRSP has been the subject of a number of analyst reports. Royal Bank of Canada reduced their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report)’s share price was down 4.7% during mid-day trading on Monday after an insider sold shares in the company. The stock traded as low as $45.16 and ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CRISPR Therapeutics AG (NASDAQ:CRSP) has reported that its CEO, Samarth Kulkarni, sold a total of $1,449,628 worth of company stock, according to a recent SEC filing. The... ZUG, Switzerland ...